|Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis|
M Verheij, R Bose, XH Lin, B Yao, WD Jarvis, S Grant, MJ Birrer, E Szabo, ...
Nature 380 (6569), 75-79, 1996
|Genomic landscape of non-small cell lung cancer in smokers and never-smokers|
R Govindan, L Ding, M Griffith, J Subramanian, ND Dees, KL Kanchi, ...
Cell 150 (6), 1121-1134, 2012
|Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals|
R Bose, M Verheij, A Haimovitz-Friedman, K Scotto, Z Fuks, R Kolesnick
Cell 82 (3), 405-414, 1995
|Whole-genome analysis informs breast cancer response to aromatase inhibition|
MJ Ellis, L Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ...
Nature 486 (7403), 353-360, 2012
|Activating HER2 mutations in HER2 gene amplification negative breast cancer|
R Bose, SM Kavuri, AC Searleman, W Shen, D Shen, DC Koboldt, ...
Cancer discovery 3 (2), 224-237, 2013
|Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts|
S Li, D Shen, J Shao, R Crowder, W Liu, A Prat, X He, S Liu, J Hoog, C Lu, ...
Cell reports 4 (6), 1116-1130, 2013
|DGIdb: mining the druggable genome|
M Griffith, OL Griffith, AC Coffman, JV Weible, JF McMichael, NC Spies, ...
Nature methods 10 (12), 1209, 2013
|Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface|
X Zhang, KA Pickin, R Bose, N Jura, PA Cole, J Kuriyan
Nature 450 (7170), 741-744, 2007
|Phosphoproteomic analysis of Her2/neu signaling and inhibition|
R Bose, H Molina, AS Patterson, JK Bitok, B Periaswamy, JS Bader, ...
Proceedings of the National Academy of Sciences 103 (26), 9773-9778, 2006
|HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment|
SM Kavuri, N Jain, F Galimi, F Cottino, SM Leto, G Migliardi, ...
Cancer Discovery 5 (8), 832-841, 2015
|Human Proteinpedia enables sharing of human protein data|
S Mathivanan, M Ahmed, NG Ahn, H Alexandre, R Amanchy, PC Andrews, ...
Nature biotechnology 26 (2), 164-167, 2008
|Mechanism of activation and inhibition of the HER4/ErbB4 kinase|
C Qiu, MK Tarrant, SH Choi, A Sathyamurthy, R Bose, S Banjade, A Pal, ...
Structure 16 (3), 460-467, 2008
|Exome sequencing and cis-regulatory mapping identify mutations in MAK, a gene encoding a regulator of ciliary length, as a cause of retinitis pigmentosa|
RK Özgül, AM Siemiatkowska, D Yücel, CA Myers, RWJ Collin, ...
The American Journal of Human Genetics 89 (2), 253-264, 2011
|The ErbB kinase domain: structural perspectives into kinase activation and inhibition|
R Bose, X Zhang
Experimental cell research 315 (4), 649-658, 2009
|Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system|
J Monsey, W Shen, P Schlesinger, R Bose
Journal of Biological Chemistry 285 (10), 7035-7044, 2010
|Analysis of the role of the C-terminal tail in the regulation of the epidermal growth factor receptor|
E Kovacs, R Das, Q Wang, TS Collier, A Cantor, Y Huang, K Wong, ...
Molecular and Cellular Biology 35 (17), 3083-3102, 2015
|Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers|
AP Boyer, TS Collier, I Vidavsky, R Bose
Molecular & Cellular Proteomics 12 (1), 180-193, 2013
|Protein tyrosine kinase–substrate interactions|
R Bose, MA Holbert, KA Pickin, PA Cole
Current opinion in structural biology 16 (6), 668-675, 2006
|Ceramide generation by the Reaper protein is not blocked by the caspase inhibitor, p35|
R Bose, P Chen, A Loconti, C Grüllich, JM Abrams, RN Kolesnick
Journal of Biological Chemistry 273 (44), 28852-28859, 1998
|HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor|
NE Ben-Baruch, R Bose, SM Kavuri, CX Ma, MJ Ellis
Journal of the National Comprehensive Cancer Network 13 (9), 1061-1064, 2015